Safety and Efficacy of Stereotactic Body Radiation Therapy for Ultra-central Thoracic Tumors: A Single Center Retrospective Review.

Int J Radiat Oncol Biol Phys

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada. Electronic address:

Published: October 2024

AI Article Synopsis

  • The study evaluated the toxicity and efficacy of stereotactic body radiation therapy (SBRT) in treating ultracentral thoracic tumors, focusing on a sample of patients treated from 2009 to 2019.
  • Out of 154 patients, a 9.4% incidence of severe toxicity occurred, with pneumonitis being the most common, while local failure rates were 14% at three years.
  • The results suggested that SBRT has relatively low rates of severe toxicity and local failure, with certain patient and treatment characteristics influencing these outcomes.

Article Abstract

Purpose: We sought to evaluate the toxicity and efficacy of stereotactic body radiation therapy (SBRT) for ultracentral thoracic tumors at our institution.

Methods And Materials: Patients with ultracentral lung tumors or nodes, defined as having the planning target volume (PTV) overlapping or abutting the central bronchial tree and/or esophagus, treated at our institution with SBRT between 2009 and 2019 were retrospectively reviewed. All SBRT plans were generated with the goal of creating homogenous dose distributions. The primary endpoint was incidence of SBRT-related grade ≥3 toxicity, defined using the Common Terminology Criteria for Adverse Events (V5.0). Secondary endpoints included local failure (LF), progression-free survival (PFS), and overall survival. Competing risk analysis was used to estimate incidence and identify predictors of severe toxicity and LF, while the Kaplan-Meier method was used to estimate PFS and OS.

Results: A total of 154 patients receiving 162 ultracentral courses of SBRT were included. The most common prescription was 50 Gy in 5 fractions (42%), with doses ranging from 30 to 55 Gy in 5 fractions (BED10 range, 48-115 Gy). The incidence of severe toxicity was 9.4% at 3 years. The most common severe toxicity was pneumonitis (n = 4). There was 1 possible treatment-related death from pneumonitis/pneumonia. Predictors of severe toxicity included increased PTV size, decreased PTV V95%, lung V5 Gy, and lung V20 Gy. The incidence of LF was 14% at 3 years. Predictors of LF included younger age and greater volume of overlap between the PTV and esophagus. The median PFS was 8.8 months, while the median overall survival was 44.0 months.

Conclusions: In the largest case series of ultracentral thoracic SBRT to date, homogenously prescribed SBRT was associated with relatively low rates of severe toxicity and LF. Predictors of toxicity should be interpreted in the context of the heterogeneity in toxicities observed.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2024.04.009DOI Listing

Publication Analysis

Top Keywords

severe toxicity
20
efficacy stereotactic
8
stereotactic body
8
body radiation
8
radiation therapy
8
thoracic tumors
8
toxicity
8
ultracentral thoracic
8
predictors severe
8
sbrt
6

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!